Engineered immune cells take on deadly childhood brain cancer
NCT ID NCT04196413
First seen Nov 20, 2025 · Last updated Apr 28, 2026 · Updated 15 times
Summary
This early-stage trial tests whether specially engineered immune cells (GD2CART) can be safely made and given to children and adults with a rare, aggressive brain or spinal cord tumor called H3K27M-mutant diffuse midline glioma. The study aims to see if the cells can be produced successfully and to find the safest dose. Participants must have already received standard radiation therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA OF SPINAL CORD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lucile Packard Children's Hospital (LPCH)
RECRUITINGStanford, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.